|
1
|
Maniakas A, Davies L and Zafereo ME:
Thyroid disease around the World. Otolaryngol Clin North Am.
51:631–642. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lupoli R, Cacciapuoti M, Tortora A, Barba
L, Verde N, Romano F, Vastarella M, Fonderico F, Masone S, Milone
M, et al: Clinical outcome in differentiated thyroid carcinoma and
microcarcinoma. Int J Surg. 12 Suppl 1:S148–S151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mercer TR and Mattick JS: Structure and
function of long noncoding RNAs in epigenetic regulation. Nat
Struct Mol Biol. 20:300–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin CY and Xu HM: Novel perspectives of
long non-coding RNAs in esophageal carcinoma. Carcinogenesis.
36:1255–1262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xie H, Ma H and Zhou D: Plasma HULC as a
promising novel biomarker for the detection of hepatocellular
carcinoma. Biomed Res Int. 2013:1361062013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang S, Dong X, Ji T, Chen G and Shan L:
Long non-coding RNA UCA1 promotes cell progression by acting as a
competing endogenous RNA of ATF2 in prostate cancer. Am J Transl
Res. 9:366–375. 2017.PubMed/NCBI
|
|
10
|
Wang X, Yang B and Ma B: The
UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate
cancer cells. Cancer Chemother Pharmacol. 78:1025–1031. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiao C, Song Z, Chen J, Zhong J, Cai W,
Tian S, Chen S, Yi Y and Xiao Y: lncRNA-UCA1 enhances cell
proliferation through functioning as a ceRNA of Sox4 in esophageal
cancer. Oncol Rep. 36:2960–2966. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang ZQ, Cai Q, Hu L, He CY, Li JF, Quan
ZW, Liu BY, Li C and Zhu ZG: Long noncoding RNA UCA1 induced by SP1
promotes cell proliferation via recruiting EZH2 and activating AKT
pathway in gastric cancer. Cell Death Dis. 8:e28392017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Gao Z, Liao J, Shang M, Li X, Yin
L, Pu Y and Liu R: lncRNA UCA1 inhibits esophageal squamous-cell
carcinoma growth by regulating the Wnt signaling pathway. J Toxicol
Environ Health A. 79:407–418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q,
Guo H and Yu C: Involvement of SRPK1 in cisplatin resistance
related to long non-coding RNA UCA1 in human ovarian cancer cells.
Neoplasma. 62:432–438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu ZY, Wang SM, Chen ZH, Huv SX, Huang K,
Huang BJ, Du JL, Huang CM, Peng L, Jian ZX and Zhao G: MiR-204
regulates HMGA2 expression and inhibits cell proliferation in human
thyroid cancer. Cancer Biomark. 15:535–542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu L, Wang J, Li X, Ma J, Shi C, Zhu H,
Xi Q, Zhang J, Zhao X and Gu M: MiR-204-5p suppresses cell
proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma.
Biochem Biophys Res Commun. 457:621–626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu
Y, Feng Y, Liu H, Fei B, Mao Y, et al: LncRNA-UCA1 enhances cell
proliferation and 5-fluorouracil resistance in colorectal cancer by
inhibiting miR-204-5p. Sci Rep. 6:238922016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saiselet M, Floor S, Tarabichi M, Dom G,
Hébrant A, van Staveren WC and Maenhaut C: Thyroid cancer cell
lines: An overview. Front Endocrinol (Lausanne).
3:1332012.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao X, Wu X, Zhang X, Hua W and Zhang Y,
Maimaiti Y, Gao Z and Zhang Y: Inhibition of BRD4 suppresses tumor
growth and enhances iodine uptake in thyroid cancer. Biochem
Biophys Res Commun. 469:679–685. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang YH, Sui XM, Sui YN, Zhu QW, Yan K,
Wang LS, Wang F and Zhou JH: BRD4 induces cell migration and
invasion in HCC cells through MMP-2 and MMP-9 activation mediated
by the Sonic hedgehog signaling pathway. Oncol Lett. 10:2227–2232.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Segura MF, Fontanals-Cirera B,
Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, González-Gomez
P, Morante M, Jubierre L, Zhang W, et al: BRD4 sustains melanoma
proliferation and represents a new target for epigenetic therapy.
Cancer Res. 73:6264–6276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Puissant A, Frumm SM, Alexe G, Bassil CF,
Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P,
et al: Targeting MYCN in neuroblastoma by BET bromodomain
inhibition. Cancer Discov. 3:308–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patel AJ, Liao CP, Chen Z, Liu C, Wang Y
and Le LQ: BET bromodomain inhibition triggers apoptosis of
NF1-associated malignant peripheral nerve sheath tumors through Bim
induction. Cell Rep. 6:81–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ott CJ, Kopp N, Bird L, Paranal RM, Qi J,
Bowman T, Rodig SJ, Kung AL, Bradner JE and Weinstock DM: BET
bromodomain inhibition targets both c-Myc and IL7R in high-risk
acute lymphoblastic leukemia. Blood. 120:2843–2852. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lockwood WW, Zejnullahu K, Bradner JE and
Varmus H: Sensitivity of human lung adenocarcinoma cell lines to
targeted inhibition of BET epigenetic signaling proteins. Proc Natl
Acad Sci USA. 109:19408–19413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Andrieu G, Tran AH, Strissel KJ and Denis
GV: BRD4 regulates breast cancer dissemination through
Jagged1/Notch1 signaling. Cancer Res. 76:6555–6567. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv
XW and Li J: Long noncoding RNAs: Novel insights into hepatocelluar
carcinoma. Cancer Lett. 344:20–27. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Sui Y, Zhu Q and Sui X:
Hsa-miR-599 suppresses the migration and invasion by targeting BRD4
in breast cancer. Oncol Lett. 14:3455–3462. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang F, Ying HQ, He BS, Pan YQ, Deng QW,
Sun HL, Chen J, Liu X and Wang SK: Upregulated lncRNA-UCA1
contributes to progression of hepatocellular carcinoma through
inhibition of miR-216b and activation of FGFR1/ERK signaling
pathway. Oncotarget. 6:7899–7917. 2015.PubMed/NCBI
|
|
31
|
Zheng Q, Wu F, Dai WY, Zheng DC, Zheng C,
Ye H, Zhou B, Chen JJ and Chen P: Aberrant expression of UCA1 in
gastric cancer and its clinical significance. Clin Transl Oncol.
17:640–646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu M, Xing LQ and Liu YJ: A three-long
noncoding RNA signature as a diagnostic biomarker for
differentiating between triple-negative and non-triple-negative
breast cancers. Medicine (Baltimore). 96:e62222017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li JH, Zhang SQ, Qiu XG, Zhang SJ, Zheng
SH and Zhang DH: Long non-coding RNA NEAT1 promotes malignant
progression of thyroid carcinoma by regulating miRNA-214. Int J
Oncol. 50:708–716. 2017. View Article : Google Scholar : PubMed/NCBI
|
